CRME - Cardiome Pharma Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.61
+0.06 (+3.87%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.55
Open1.57
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.55 - 1.61
52 Week Range1.29 - 4.84
Volume71,574
Avg. Volume122,246
Market Cap54.685M
Beta-0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.91
Trade prices are not sourced from all markets
  • CNW Group20 hours ago

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

  • PR Newswire20 hours ago

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

    Addition of High-Risk STEMI Patients Significantly Expands the Number of Patients in Which Aggrastat Can Be Used NASDAQ:CRME  TSX:COM VANCOUVER , Jan. 23, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME ...

  • CNW Group14 days ago

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

  • PR Newswire14 days ago

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

    NASDAQ:CRME TSX:COM VANCOUVER , Jan. 10, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • CNW Grouplast month

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

  • PR Newswirelast month

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    VANCOUVER, Dec. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia. Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide. Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

  • With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?
    Simply Wall St.last month

    With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?

    After looking at Cardiome Pharma Corp’s (TSX:COM) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • PR Newswirelast month

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (STDY) has reached agreement with the U.S. Food and Drug Administration (FDA) on the work necessary to resubmit the New Drug Application (NDA) for Trevyent® for the treatment of pulmonary arterial hypertension (PAH). Based on written feedback received from the FDA, SteadyMed indicated that is not required to conduct any clinical trials to prove the safety or efficacy of Trevyent and that the FDA has agreed that certain in vitro design verification (DV) tests on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and process validation, should be adequate for the resubmission and acceptance of the 505(b)(2) NDA.

  • CNW Grouplast month

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

  • PR Newswirelast month

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy (OPAT) Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December 11-12, 2017 in Birmingham, UK. The Company-sponsored plenary symposium, titled, "Managing serious skin infections within the changing NHS, time for a rethink?" will feature presentations by three physician experts describing treatment and patient experience with Cardiome's Xydalba™ (dalbavancin hydrochloride), the first and only 30-minute, one-dose treatment option for acute bacterial skin and skin structure infections. Cardiome currently markets Xydalba in France, Germany, the UK, the Republic of Ireland, Belgium, Finland and Sweden.

  • CNW Grouplast month

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
    Capital Cube2 months ago

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Aeterna Zentaris Inc. and Novelion Therapeutics Inc. (AEZS-US and NVLN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.02 ... Read more (Read more...)

  • PR Newswire2 months ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    VANCOUVER, Nov. 20, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz, Chief Financial Officer of Cardiome, will present at the 29th Annual Piper Jaffray Healthcare Conference. The presentation will take place at the Lotte New York Palace on Tuesday, November 28, 2017 at 2:30 p.m. EDT.

  • CNW Group2 months ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

  • Associated Press2 months ago

    Cardiome reports 3Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 20 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by ...

  • CNW Group2 months ago

    Cardiome Reports Third Quarter 2017 Financial Results

    Cardiome Reports Third Quarter 2017 Financial Results

  • PR Newswire2 months ago

    Cardiome Reports Third Quarter 2017 Financial Results

    NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, November 14, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME ...

  • ACCESSWIRE2 months ago

    Cardiome Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 4:30 ...

  • PR Newswire3 months ago

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    VANCOUVER, Nov. 7, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that it will report financial results for the third quarter ended September 30, 2017 on Tuesday, November 14, 2017. Cardiome will hold a conference call and webcast at 4:30 p.m. Eastern (1:30 p.m. Pacific) on that day to discuss the results. To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 66802456.

  • CNW Group3 months ago

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

  • What’s Installed For Cardiome Pharma Corp (TSX:COM)?
    Simply Wall St.3 months ago

    What’s Installed For Cardiome Pharma Corp (TSX:COM)?

    Cardiome Pharma Corp (TSX:COM), a CADCA$70.60M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • PR Newswire3 months ago

    Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

    VANCOUVER, Nov. 2, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the expansion of its geographic presence for Brinavess (vernakalant hydrochloride, IV) into the two new key territories of South Africa and Pakistan.  Following the recent receipt of authorization from South Africa's Department of Health, Brinavess was launched in South Africa by Cardiome's partner Aspen Medical, preparing for the first sale of the product on the African continent. Cardiome is eligible to receive payments from Aspen Medical based on pre-specified annual commercial goals.  Aspen Medical, who also markets Aggrastat® in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.  In addition to this commercial launch, a Cardiome affiliate, Correvio International Sàrl, entered into an exclusive license and distribution agreement with ATCO Laboratories Limited that will advance Brinavess toward commercialization in Pakistan.  Under the terms of the license agreement, ATCO will be responsible for obtaining, at its own cost, regulatory and pricing approvals for Brinavess from the Drug Regulatory Authority of Pakistan, then executing the commercial launch and subsequent sale and marketing of Brinavess in the territory.

  • CNW Group3 months ago

    Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

    Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

  • CNW Group3 months ago

    Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies

    Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies

  • Cardiome Pharma Corp (TSX:COM): Time For A Financial Health Check
    Simply Wall St.3 months ago

    Cardiome Pharma Corp (TSX:COM): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like Cardiome Pharma Corp (TSX:COM), with a market cap of USD $76.81M. However, an important fact which most ignore is: howRead More...